CA2823935A1 - Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof - Google Patents
Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof Download PDFInfo
- Publication number
- CA2823935A1 CA2823935A1 CA2823935A CA2823935A CA2823935A1 CA 2823935 A1 CA2823935 A1 CA 2823935A1 CA 2823935 A CA2823935 A CA 2823935A CA 2823935 A CA2823935 A CA 2823935A CA 2823935 A1 CA2823935 A1 CA 2823935A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrrolo
- pyrimidin
- methyl
- octane
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract description 3
- RNFIBTDXEXGJBV-UHFFFAOYSA-N piperazine;sulfamide Chemical class NS(N)(=O)=O.C1CNCCN1 RNFIBTDXEXGJBV-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 329
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 11
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 11
- 230000001363 autoimmune Effects 0.000 claims abstract description 10
- 239000012453 solvate Substances 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 9
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 9
- 102000042838 JAK family Human genes 0.000 claims abstract description 9
- 108091082332 JAK family Proteins 0.000 claims abstract description 9
- 241001303601 Rosacea Species 0.000 claims abstract description 9
- 208000024799 Thyroid disease Diseases 0.000 claims abstract description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 9
- 208000006673 asthma Diseases 0.000 claims abstract description 9
- 208000030533 eye disease Diseases 0.000 claims abstract description 9
- 208000032839 leukemia Diseases 0.000 claims abstract description 9
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 9
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 9
- 201000004700 rosacea Diseases 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 8
- 150000004677 hydrates Chemical class 0.000 claims abstract description 5
- 229940002612 prodrug Drugs 0.000 claims abstract description 5
- 239000000651 prodrug Substances 0.000 claims abstract description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 351
- -1 cyano, hydroxy Chemical group 0.000 claims description 250
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 146
- 125000000623 heterocyclic group Chemical group 0.000 claims description 122
- UIEQYZNDSLCTMK-UHFFFAOYSA-N octane-4-sulfonic acid Chemical compound CCCCC(S(O)(=O)=O)CCC UIEQYZNDSLCTMK-UHFFFAOYSA-N 0.000 claims description 111
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 108
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 239000001257 hydrogen Substances 0.000 claims description 68
- 125000003118 aryl group Chemical group 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 59
- 125000001072 heteroaryl group Chemical group 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 51
- 125000004043 oxo group Chemical group O=* 0.000 claims description 51
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 125000004432 carbon atom Chemical group C* 0.000 claims description 45
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 44
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 42
- 150000002367 halogens Chemical group 0.000 claims description 40
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 40
- 150000002431 hydrogen Chemical group 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 32
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 30
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 18
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 17
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 17
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 16
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 13
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 13
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 12
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 11
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 210000000987 immune system Anatomy 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 9
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000002458 infectious effect Effects 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical class COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010039705 Scleritis Diseases 0.000 claims description 4
- 206010040799 Skin atrophy Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 4
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- GUMBNOITRNRLCS-UHFFFAOYSA-N n-methyl-2-phenoxyethanamine Chemical compound CNCCOC1=CC=CC=C1 GUMBNOITRNRLCS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010015084 Episcleritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 241001420836 Ophthalmitis Species 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000010403 panophthalmitis Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 8
- JALJYLNIVJITOC-UHFFFAOYSA-N 7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonic acid Chemical compound OS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 JALJYLNIVJITOC-UHFFFAOYSA-N 0.000 claims 5
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- UPBPAKISEVOITE-MSXFZWOLSA-N (NZ)-N-[(4-methoxyphenyl)methylidene]-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1=CC(OC)=CC=C1\C=N/S(=O)(=O)N1C2(CC2)CN(C=2C=3C=CNC=3N=CN=2)CC1 UPBPAKISEVOITE-MSXFZWOLSA-N 0.000 claims 1
- PIDLOAOWCYMMHN-UHFFFAOYSA-N 1-[[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]piperidine-3-carbonitrile Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N1CCCC(C#N)C1 PIDLOAOWCYMMHN-UHFFFAOYSA-N 0.000 claims 1
- LJNYZRGQGRKNRP-UHFFFAOYSA-N 1-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]piperidine-4-carbonitrile Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N1CCC(C#N)CC1 LJNYZRGQGRKNRP-UHFFFAOYSA-N 0.000 claims 1
- ZVHLOQRQRCTGEO-UHFFFAOYSA-N 2-(1,1-dioxothian-4-yl)-n-methyl-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]acetamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)CC1CCS(=O)(=O)CC1 ZVHLOQRQRCTGEO-UHFFFAOYSA-N 0.000 claims 1
- FMBSAYNKWUSSNX-UHFFFAOYSA-N 2-(1,1-dioxothiolan-3-yl)-N-methyl-N-[[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]acetamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)CC1CCS(=O)(=O)C1 FMBSAYNKWUSSNX-UHFFFAOYSA-N 0.000 claims 1
- DRXAZKROKYSBAZ-UHFFFAOYSA-N 2-cyclopentyl-n-methyl-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]acetamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)CC1CCCC1 DRXAZKROKYSBAZ-UHFFFAOYSA-N 0.000 claims 1
- VVZYKTKWNPJKNW-UHFFFAOYSA-N 3,3,3-trifluoro-n-methyl-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]propanamide Chemical compound FC(F)(F)CC(=O)N(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 VVZYKTKWNPJKNW-UHFFFAOYSA-N 0.000 claims 1
- KVHKBPLCAITBRO-UHFFFAOYSA-N 3-(1,1-dioxothiolan-3-yl)-N-methyl-N-[[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]propanamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)CCC1CCS(=O)(=O)C1 KVHKBPLCAITBRO-UHFFFAOYSA-N 0.000 claims 1
- OZKAPOUXJYTSAI-UHFFFAOYSA-N 3-cyclopentyl-n-methyl-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]propanamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)CCC1CCCC1 OZKAPOUXJYTSAI-UHFFFAOYSA-N 0.000 claims 1
- OZLKUNKEBURGNH-UHFFFAOYSA-N 4-(2-phenylethylamino)butanenitrile Chemical compound N#CCCCNCCC1=CC=CC=C1 OZLKUNKEBURGNH-UHFFFAOYSA-N 0.000 claims 1
- PODDKJDNQSSKHD-UHFFFAOYSA-N 4-(4-piperidin-1-ylsulfonyl-4,7-diazaspiro[2.5]octan-7-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N1CCCCC1 PODDKJDNQSSKHD-UHFFFAOYSA-N 0.000 claims 1
- NMMOWASTGBPHTO-UHFFFAOYSA-N N-(2,2-diphenylethyl)-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMMOWASTGBPHTO-UHFFFAOYSA-N 0.000 claims 1
- XFYAOSWNQLKSOT-UHFFFAOYSA-N N-(2-methoxyethyl)-N-(2-phenylethyl)-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCOC)CCC1=CC=CC=C1 XFYAOSWNQLKSOT-UHFFFAOYSA-N 0.000 claims 1
- GZZHZUCELYUDTF-UHFFFAOYSA-N N-(3-cyanopropyl)-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCCCN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 GZZHZUCELYUDTF-UHFFFAOYSA-N 0.000 claims 1
- LATMSELDCZIDDC-UHFFFAOYSA-N N-(4-cyanobutyl)-N-(2-phenylethyl)-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCCCC#N)CCC1=CC=CC=C1 LATMSELDCZIDDC-UHFFFAOYSA-N 0.000 claims 1
- YFERPDDHNCYXOF-UHFFFAOYSA-N N-(azetidin-3-yl)-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1CNC1 YFERPDDHNCYXOF-UHFFFAOYSA-N 0.000 claims 1
- GTSKKXYSCFTTPE-UHFFFAOYSA-N N-[(1,1-dioxothiolan-3-yl)methyl]-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NCC1CCS(=O)(=O)C1 GTSKKXYSCFTTPE-UHFFFAOYSA-N 0.000 claims 1
- CBAWBLHQVSTOSY-UHFFFAOYSA-N N-[(1,1-dioxothiolan-3-yl)methyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCS(=O)(=O)C1 CBAWBLHQVSTOSY-UHFFFAOYSA-N 0.000 claims 1
- RAFNKNDYDNGOAD-UHFFFAOYSA-N N-[(2-cyanophenyl)methyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC=C1C#N RAFNKNDYDNGOAD-UHFFFAOYSA-N 0.000 claims 1
- VCFLUFTWBWEFFW-UHFFFAOYSA-N N-[(4-fluorophenyl)methyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(F)C=C1 VCFLUFTWBWEFFW-UHFFFAOYSA-N 0.000 claims 1
- FRGOJTCBTIPUFW-UHFFFAOYSA-N N-[3-(4-cyanophenyl)propyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCCC1=CC=C(C#N)C=C1 FRGOJTCBTIPUFW-UHFFFAOYSA-N 0.000 claims 1
- VUELUIFCCDJRAJ-UHFFFAOYSA-N N-[[2-(2,2-difluoroethyl)-1,5-dihydropyrazol-5-yl]methyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1NN(CC(F)F)C=C1 VUELUIFCCDJRAJ-UHFFFAOYSA-N 0.000 claims 1
- AXIKLLWMQWXJLL-UHFFFAOYSA-N N-[[2-(difluoromethyl)-1,5-dihydropyrazol-5-yl]methyl]-N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1NN(C(F)F)C=C1 AXIKLLWMQWXJLL-UHFFFAOYSA-N 0.000 claims 1
- YEYROOIIGBHGKT-UHFFFAOYSA-N N-methyl-1,1-dioxo-N-[[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]thiane-3-carboxamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)C1CCCS(=O)(=O)C1 YEYROOIIGBHGKT-UHFFFAOYSA-N 0.000 claims 1
- JNNRXBHLOPWRBQ-UHFFFAOYSA-N N-methyl-1,1-dioxo-N-[[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]thiane-4-carboxamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)C1CCS(=O)(=O)CC1 JNNRXBHLOPWRBQ-UHFFFAOYSA-N 0.000 claims 1
- IHSSPJIVZWYYOV-UHFFFAOYSA-N N-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethyl)phenyl]methyl]-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(C(F)(F)F)C=C1 IHSSPJIVZWYYOV-UHFFFAOYSA-N 0.000 claims 1
- XZOWIJDBQIHMFC-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O.CCCC(N)=O XZOWIJDBQIHMFC-UHFFFAOYSA-N 0.000 claims 1
- VJWGOFWWFKQZDA-UHFFFAOYSA-N methyl 2-[methyl-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]amino]acetate Chemical compound COC(=O)CN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 VJWGOFWWFKQZDA-UHFFFAOYSA-N 0.000 claims 1
- HAKIEOJHJVCDIL-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound OCCN(CCO)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 HAKIEOJHJVCDIL-UHFFFAOYSA-N 0.000 claims 1
- DNORSFDDCWTUFQ-UHFFFAOYSA-N n,n-bis(3-cyanopropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCCCN(CCCC#N)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 DNORSFDDCWTUFQ-UHFFFAOYSA-N 0.000 claims 1
- KWMPMCMYYNOWGJ-UHFFFAOYSA-N n,n-bis(cyanomethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCN(CC#N)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 KWMPMCMYYNOWGJ-UHFFFAOYSA-N 0.000 claims 1
- FUPKHUVJMKSHTA-UHFFFAOYSA-N n,n-bis[(4,4-difluorocyclohexyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CC(F)(F)CCC1CN(S(=O)(=O)N1C2(CC2)CN(CC1)C=1C=2C=CNC=2N=CN=1)CC1CCC(F)(F)CC1 FUPKHUVJMKSHTA-UHFFFAOYSA-N 0.000 claims 1
- SIYUZCGZDKSFNK-UHFFFAOYSA-N n,n-dibenzyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 SIYUZCGZDKSFNK-UHFFFAOYSA-N 0.000 claims 1
- NMEYIHPSPMHXGR-UHFFFAOYSA-N n,n-dimethyl-2-[methyl-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]amino]acetamide Chemical compound CN(C)C(=O)CN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 NMEYIHPSPMHXGR-UHFFFAOYSA-N 0.000 claims 1
- BVRCTLKZFRJXRZ-UHFFFAOYSA-N n,n-dimethyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 BVRCTLKZFRJXRZ-UHFFFAOYSA-N 0.000 claims 1
- AKCHNGMARMCTRL-UHFFFAOYSA-N n-(2-cyanoethyl)-n-(cyanomethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCCN(CC#N)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 AKCHNGMARMCTRL-UHFFFAOYSA-N 0.000 claims 1
- BIUAPLZVGLZVPH-UHFFFAOYSA-N n-(2-cyanoethyl)-n-(oxolan-2-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCC#N)CC1CCCO1 BIUAPLZVGLZVPH-UHFFFAOYSA-N 0.000 claims 1
- VPSXOPWYBDTTPU-UHFFFAOYSA-N n-(2-cyanoethyl)-n-cyclopropyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCC#N)C1CC1 VPSXOPWYBDTTPU-UHFFFAOYSA-N 0.000 claims 1
- ICZGHMFIOVJIKB-UHFFFAOYSA-N n-(2-cyclohexylethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1CCCCC1 ICZGHMFIOVJIKB-UHFFFAOYSA-N 0.000 claims 1
- ATNZFGAQUNLOJV-UHFFFAOYSA-N n-(2-cyclopentylethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1CCCC1 ATNZFGAQUNLOJV-UHFFFAOYSA-N 0.000 claims 1
- SUHHXRISGRZNAI-UHFFFAOYSA-N n-(2-cyclopropylethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1CC1 SUHHXRISGRZNAI-UHFFFAOYSA-N 0.000 claims 1
- XDBNIYMUBIDISM-UHFFFAOYSA-N n-(2-hydroxyethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound OCCNS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 XDBNIYMUBIDISM-UHFFFAOYSA-N 0.000 claims 1
- JSEVRNJZODIHEC-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCO)CCC1=CC=CC=C1 JSEVRNJZODIHEC-UHFFFAOYSA-N 0.000 claims 1
- YEXDARNQPFGTOB-UHFFFAOYSA-N n-(2-hydroxyethyl)-n-propan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound OCCN(C(C)C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 YEXDARNQPFGTOB-UHFFFAOYSA-N 0.000 claims 1
- OXLLIFVNWVIAQB-UHFFFAOYSA-N n-(2-methylpropyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC(C)C)CCC1=CC=CC=C1 OXLLIFVNWVIAQB-UHFFFAOYSA-N 0.000 claims 1
- UWMSPUUIHLRSFV-UHFFFAOYSA-N n-(2-oxobutyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC(=O)CC)CCC1=CC=CC=C1 UWMSPUUIHLRSFV-UHFFFAOYSA-N 0.000 claims 1
- YKPBEWKMOVHBLR-UHFFFAOYSA-N n-(2-phenylethyl)-n-(2-pyrazol-1-ylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCN1N=CC=C1)CCC1=CC=CC=C1 YKPBEWKMOVHBLR-UHFFFAOYSA-N 0.000 claims 1
- IBLNEBOCMPEHLE-UHFFFAOYSA-N n-(2-phenylethyl)-n-(3-phenylpropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 IBLNEBOCMPEHLE-UHFFFAOYSA-N 0.000 claims 1
- PTSWVAXXEMTETP-UHFFFAOYSA-N n-(2-phenylethyl)-n-propyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCC)CCC1=CC=CC=C1 PTSWVAXXEMTETP-UHFFFAOYSA-N 0.000 claims 1
- WZFXRNWVRCNKPF-UHFFFAOYSA-N n-(3-cyanopropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCCCNS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 WZFXRNWVRCNKPF-UHFFFAOYSA-N 0.000 claims 1
- ACOPWBKJITVHHX-UHFFFAOYSA-N n-(3-cyanopropyl)-n-(3-phenylpropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCCC#N)CCCC1=CC=CC=C1 ACOPWBKJITVHHX-UHFFFAOYSA-N 0.000 claims 1
- XANXFARMEPQEHF-UHFFFAOYSA-N n-(3-cyanopropyl)-n-cyclobutyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCCC#N)C1CCC1 XANXFARMEPQEHF-UHFFFAOYSA-N 0.000 claims 1
- GQDWVMLGHJQKNE-UHFFFAOYSA-N n-(3-hydroxypropyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCCO)CCC1=CC=CC=C1 GQDWVMLGHJQKNE-UHFFFAOYSA-N 0.000 claims 1
- NYVSWDGDOBILKU-UHFFFAOYSA-N n-(cyanomethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC#N)CCC1=CC=CC=C1 NYVSWDGDOBILKU-UHFFFAOYSA-N 0.000 claims 1
- NICFBFHTBZISBG-UHFFFAOYSA-N n-(cyanomethyl)-n-cyclobutyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC#N)C1CCC1 NICFBFHTBZISBG-UHFFFAOYSA-N 0.000 claims 1
- IOJSBENOGFHMSY-UHFFFAOYSA-N n-(cyanomethyl)-n-propan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N#CCN(C(C)C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 IOJSBENOGFHMSY-UHFFFAOYSA-N 0.000 claims 1
- DCNSJGOMFIRNTM-UHFFFAOYSA-N n-(cyclobutylmethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC1CCC1)CCC1=CC=CC=C1 DCNSJGOMFIRNTM-UHFFFAOYSA-N 0.000 claims 1
- YOCSHVIPBWMION-UHFFFAOYSA-N n-(cyclobutylmethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCC1 YOCSHVIPBWMION-UHFFFAOYSA-N 0.000 claims 1
- RFLHUCDNNJIDAA-UHFFFAOYSA-N n-(cyclohexylmethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC1CCCCC1)CCC1=CC=CC=C1 RFLHUCDNNJIDAA-UHFFFAOYSA-N 0.000 claims 1
- WWUIOYQXZCNABQ-UHFFFAOYSA-N n-(cyclopentylmethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCCC1 WWUIOYQXZCNABQ-UHFFFAOYSA-N 0.000 claims 1
- OGFCLXVEUGEEII-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC1CC1)CCC1=CC=CC=C1 OGFCLXVEUGEEII-UHFFFAOYSA-N 0.000 claims 1
- XWPDTEIVYWUYOI-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CC1 XWPDTEIVYWUYOI-UHFFFAOYSA-N 0.000 claims 1
- VEUWFKFJIDJALQ-UHFFFAOYSA-N n-(oxan-2-ylmethyl)-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC1OCCCC1)CCC1=CC=CC=C1 VEUWFKFJIDJALQ-UHFFFAOYSA-N 0.000 claims 1
- QZCWVDFYUVZLOE-UHFFFAOYSA-N n-[(1,1-dioxothian-3-yl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCCS(=O)(=O)C1 QZCWVDFYUVZLOE-UHFFFAOYSA-N 0.000 claims 1
- YJUQDNGJUALGNC-UHFFFAOYSA-N n-[(1,1-dioxothian-4-yl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NCC1CCS(=O)(=O)CC1 YJUQDNGJUALGNC-UHFFFAOYSA-N 0.000 claims 1
- VZMOUDKNFDGYAK-UHFFFAOYSA-N n-[(1-formylpyrrolidin-3-yl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCN(C=O)C1 VZMOUDKNFDGYAK-UHFFFAOYSA-N 0.000 claims 1
- YUTJNOBDAQEGDI-UHFFFAOYSA-N n-[(2,2-difluorocyclopropyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CC1(F)F YUTJNOBDAQEGDI-UHFFFAOYSA-N 0.000 claims 1
- HJTCDJXGYYUHTB-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC=C1F HJTCDJXGYYUHTB-UHFFFAOYSA-N 0.000 claims 1
- SPMXMUUWHSTVNZ-UHFFFAOYSA-N n-[(3,3-difluorocyclobutyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CC(F)(F)C1 SPMXMUUWHSTVNZ-UHFFFAOYSA-N 0.000 claims 1
- HRADOEZPBWGFQO-UHFFFAOYSA-N n-[(3-cyanophenyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC(C#N)=C1 HRADOEZPBWGFQO-UHFFFAOYSA-N 0.000 claims 1
- ISZKDSFWTVXKEF-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC(F)=C1 ISZKDSFWTVXKEF-UHFFFAOYSA-N 0.000 claims 1
- FHZSSVVAFHRPBF-UHFFFAOYSA-N n-[(4,4-difluorocyclohexyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CC(F)(F)CCC1CNS(=O)(=O)N1C2(CC2)CN(C=2C=3C=CNC=3N=CN=2)CC1 FHZSSVVAFHRPBF-UHFFFAOYSA-N 0.000 claims 1
- UTEWAPMHZXUCTB-UHFFFAOYSA-N n-[(4,4-difluorocyclohexyl)methyl]-n-ethyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC)CC1CCC(F)(F)CC1 UTEWAPMHZXUCTB-UHFFFAOYSA-N 0.000 claims 1
- AXCRXYDVQZNBOX-UHFFFAOYSA-N n-[(4,4-difluorocyclohexyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCC(F)(F)CC1 AXCRXYDVQZNBOX-UHFFFAOYSA-N 0.000 claims 1
- GRDFUHURZJXXCQ-UHFFFAOYSA-N n-[(4-cyanophenyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(C#N)C=C1 GRDFUHURZJXXCQ-UHFFFAOYSA-N 0.000 claims 1
- JBQQYFNYVHVADI-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1=CC(OC)=CC=C1CNS(=O)(=O)N1C2(CC2)CN(C=2C=3C=CNC=3N=CN=2)CC1 JBQQYFNYVHVADI-UHFFFAOYSA-N 0.000 claims 1
- RSGVWZUYASWQCB-UHFFFAOYSA-N n-[(4-tert-butylcyclohexyl)methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCC(C(C)(C)C)CC1 RSGVWZUYASWQCB-UHFFFAOYSA-N 0.000 claims 1
- HWWQPMHGMJYQBX-UHFFFAOYSA-N n-[2-(1,1-dioxothiolan-3-yl)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1CCS(=O)(=O)C1 HWWQPMHGMJYQBX-UHFFFAOYSA-N 0.000 claims 1
- BWWHRNNDHFETGY-UHFFFAOYSA-N n-[2-(2-cyanophenoxy)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCOC1=CC=CC=C1C#N BWWHRNNDHFETGY-UHFFFAOYSA-N 0.000 claims 1
- QXWOWCWDETVASJ-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)S(=O)(=O)N1C2(CC2)CN(C=2C=3C=CNC=3N=CN=2)CC1 QXWOWCWDETVASJ-UHFFFAOYSA-N 0.000 claims 1
- GKNYDHLHNZPDEH-UHFFFAOYSA-N n-[2-(3-cyanophenoxy)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCOC1=CC=CC(C#N)=C1 GKNYDHLHNZPDEH-UHFFFAOYSA-N 0.000 claims 1
- KGQSNZCHXMVUOG-UHFFFAOYSA-N n-[2-(3-fluorophenyl)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1=CC=CC(F)=C1 KGQSNZCHXMVUOG-UHFFFAOYSA-N 0.000 claims 1
- MYUXLKVLFFVJOE-UHFFFAOYSA-N n-[2-(4-chlorophenoxy)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCOC1=CC=C(Cl)C=C1 MYUXLKVLFFVJOE-UHFFFAOYSA-N 0.000 claims 1
- XWOHIVREEIWKFO-UHFFFAOYSA-N n-[2-(4-cyanophenoxy)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCOC1=CC=C(C#N)C=C1 XWOHIVREEIWKFO-UHFFFAOYSA-N 0.000 claims 1
- PGIWJLXKPPEEIK-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1=CC=C(F)C=C1 PGIWJLXKPPEEIK-UHFFFAOYSA-N 0.000 claims 1
- YKNUUZAYMADJRY-LDCVWXEPSA-N n-[[(2r)-1-(2,3-dihydroxypropanoyl)pyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1C(=O)C(O)CO YKNUUZAYMADJRY-LDCVWXEPSA-N 0.000 claims 1
- HHVBSINVBMCTHX-MRXNPFEDSA-N n-[[(2r)-1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1C(=O)CC#N HHVBSINVBMCTHX-MRXNPFEDSA-N 0.000 claims 1
- NHRCAZVIQFZGRF-QGZVFWFLSA-N n-[[(2r)-1-(3-cyanopropanoyl)pyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1C(=O)CCC#N NHRCAZVIQFZGRF-QGZVFWFLSA-N 0.000 claims 1
- MVOYGCXBJNKIAH-MRXNPFEDSA-N n-[[(2r)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1C(=O)CCO MVOYGCXBJNKIAH-MRXNPFEDSA-N 0.000 claims 1
- XSKPFWRMXQQJSH-OAHLLOKOSA-N n-[[(2r)-1-formylpyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1C=O XSKPFWRMXQQJSH-OAHLLOKOSA-N 0.000 claims 1
- MVOYGCXBJNKIAH-INIZCTEOSA-N n-[[(2s)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@@H]1CCCN1C(=O)CCO MVOYGCXBJNKIAH-INIZCTEOSA-N 0.000 claims 1
- MVYSFSRTFBYGAR-FQEVSTJZSA-N n-[[(2s)-1-benzylpyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C([C@H]1CNS(=O)(=O)N2C3(CC3)CN(CC2)C=2C=3C=CNC=3N=CN=2)CCN1CC1=CC=CC=C1 MVYSFSRTFBYGAR-FQEVSTJZSA-N 0.000 claims 1
- XSKPFWRMXQQJSH-HNNXBMFYSA-N n-[[(2s)-1-formylpyrrolidin-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@@H]1CCCN1C=O XSKPFWRMXQQJSH-HNNXBMFYSA-N 0.000 claims 1
- RQCMCKFZYROOTM-UHFFFAOYSA-N n-[[5-(dimethylsulfamoyl)furan-2-yl]methyl]-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound O1C(S(=O)(=O)N(C)C)=CC=C1CN(C)S(=O)(=O)N1C2(CC2)CN(C=2C=3C=CNC=3N=CN=2)CC1 RQCMCKFZYROOTM-UHFFFAOYSA-N 0.000 claims 1
- XCSUFNKLTGYLGI-UHFFFAOYSA-N n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]formamide Chemical compound O=CNS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 XCSUFNKLTGYLGI-UHFFFAOYSA-N 0.000 claims 1
- KEONGVXNLBBNIL-UHFFFAOYSA-N n-benzyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NCC1=CC=CC=C1 KEONGVXNLBBNIL-UHFFFAOYSA-N 0.000 claims 1
- CFQGNFZUKREFNE-UHFFFAOYSA-N n-benzyl-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC=C1 CFQGNFZUKREFNE-UHFFFAOYSA-N 0.000 claims 1
- UAUSGHZYCFDFOG-UHFFFAOYSA-N n-but-2-ynyl-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC#CC)CCC1=CC=CC=C1 UAUSGHZYCFDFOG-UHFFFAOYSA-N 0.000 claims 1
- JJIIWABQMOCAJY-UHFFFAOYSA-N n-cyclobutyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NC1CCC1 JJIIWABQMOCAJY-UHFFFAOYSA-N 0.000 claims 1
- ZXVPQAYRROPSID-UHFFFAOYSA-N n-cyclobutyl-n-(2-hydroxyethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCO)C1CCC1 ZXVPQAYRROPSID-UHFFFAOYSA-N 0.000 claims 1
- MIUQCLGIQMDLRR-UHFFFAOYSA-N n-cyclobutyl-n-(2-imidazol-1-ylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C1CCC1)CCN1C=CN=C1 MIUQCLGIQMDLRR-UHFFFAOYSA-N 0.000 claims 1
- IXHWJTUUJORBAX-UHFFFAOYSA-N n-cyclobutyl-n-(2-methoxyethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCOC)C1CCC1 IXHWJTUUJORBAX-UHFFFAOYSA-N 0.000 claims 1
- ICBUVEURXRUENW-UHFFFAOYSA-N n-cyclobutyl-n-[3-(dimethylamino)propyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CCCN(C)C)C1CCC1 ICBUVEURXRUENW-UHFFFAOYSA-N 0.000 claims 1
- POLPFFPBRUEOFX-UHFFFAOYSA-N n-cyclobutyl-n-ethyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(CC)C1CCC1 POLPFFPBRUEOFX-UHFFFAOYSA-N 0.000 claims 1
- GRPZFLWGRGVWBR-UHFFFAOYSA-N n-cyclobutyl-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1CCC1 GRPZFLWGRGVWBR-UHFFFAOYSA-N 0.000 claims 1
- WBNLSRCHYHPRAV-UHFFFAOYSA-N n-cyclopentyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NC1CCCC1 WBNLSRCHYHPRAV-UHFFFAOYSA-N 0.000 claims 1
- SZRDJSMRSZTEAJ-UHFFFAOYSA-N n-cyclopentyl-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1CCCC1 SZRDJSMRSZTEAJ-UHFFFAOYSA-N 0.000 claims 1
- CMWWGIDJXSETJU-UHFFFAOYSA-N n-cyclopropyl-n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1CC1 CMWWGIDJXSETJU-UHFFFAOYSA-N 0.000 claims 1
- JKJTWLYTMLZRNQ-UHFFFAOYSA-N n-ethyl-n-propan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CCN(C(C)C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 JKJTWLYTMLZRNQ-UHFFFAOYSA-N 0.000 claims 1
- BFFDHARZVZZRSG-UHFFFAOYSA-N n-methyl-1,1-dioxo-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]thiolane-3-carboxamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)C1CCS(=O)(=O)C1 BFFDHARZVZZRSG-UHFFFAOYSA-N 0.000 claims 1
- OZGDUZIROORKOP-UHFFFAOYSA-N n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-n-(2-pyrrol-1-ylethyl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCN1C=CC=C1 OZGDUZIROORKOP-UHFFFAOYSA-N 0.000 claims 1
- ALNGQLRSOWJELW-UHFFFAOYSA-N n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-n-[(3-sulfamoylphenyl)methyl]-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC(S(N)(=O)=O)=C1 ALNGQLRSOWJELW-UHFFFAOYSA-N 0.000 claims 1
- VXWQQULEGHVBNQ-UHFFFAOYSA-N n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-n-[(4-sulfamoylphenyl)methyl]-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(S(N)(=O)=O)C=C1 VXWQQULEGHVBNQ-UHFFFAOYSA-N 0.000 claims 1
- AAAGJSQSBKHFJZ-UHFFFAOYSA-N n-methyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-n-[[4-(trifluoromethoxy)phenyl]methyl]-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(OC(F)(F)F)C=C1 AAAGJSQSBKHFJZ-UHFFFAOYSA-N 0.000 claims 1
- WJMJAADAYUHNKO-UHFFFAOYSA-N n-methyl-n-(1,2-oxazol-5-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=NO1 WJMJAADAYUHNKO-UHFFFAOYSA-N 0.000 claims 1
- HDCSBLGQWXCZAQ-UHFFFAOYSA-N n-methyl-n-(1-methylsulfonylazetidin-3-yl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1CN(S(C)(=O)=O)C1 HDCSBLGQWXCZAQ-UHFFFAOYSA-N 0.000 claims 1
- JKIBSGYPVPXSSJ-UHFFFAOYSA-N n-methyl-n-(2-phenylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCC1=CC=CC=C1 JKIBSGYPVPXSSJ-UHFFFAOYSA-N 0.000 claims 1
- MOYZRHBDPGHISH-UHFFFAOYSA-N n-methyl-n-(2-phenylpropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C=1C=CC=CC=1C(C)CN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 MOYZRHBDPGHISH-UHFFFAOYSA-N 0.000 claims 1
- OPZXZFJPENFDEN-UHFFFAOYSA-N n-methyl-n-(2-pyrazol-1-ylethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCN1C=CC=N1 OPZXZFJPENFDEN-UHFFFAOYSA-N 0.000 claims 1
- SUNHRONPTOLOOS-UHFFFAOYSA-N n-methyl-n-(3-methylbutyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CC(C)CCN(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 SUNHRONPTOLOOS-UHFFFAOYSA-N 0.000 claims 1
- CDPCTSMMJVXMIP-UHFFFAOYSA-N n-methyl-n-(3-phenylpropyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CCCC1=CC=CC=C1 CDPCTSMMJVXMIP-UHFFFAOYSA-N 0.000 claims 1
- KTNQDUXBGJMUBH-UHFFFAOYSA-N n-methyl-n-(oxan-2-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCCCO1 KTNQDUXBGJMUBH-UHFFFAOYSA-N 0.000 claims 1
- SNZZBONCBHGLIU-UHFFFAOYSA-N n-methyl-n-(oxan-4-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCOCC1 SNZZBONCBHGLIU-UHFFFAOYSA-N 0.000 claims 1
- VUHGZQGWQRJXMM-UHFFFAOYSA-N n-methyl-n-(piperidin-3-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCCNC1 VUHGZQGWQRJXMM-UHFFFAOYSA-N 0.000 claims 1
- MSLHZOFWBKGJCI-UHFFFAOYSA-N n-methyl-n-(piperidin-4-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCNCC1 MSLHZOFWBKGJCI-UHFFFAOYSA-N 0.000 claims 1
- BXXYCUSSZNLKLG-UHFFFAOYSA-N n-methyl-n-(pyridin-2-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=CC=N1 BXXYCUSSZNLKLG-UHFFFAOYSA-N 0.000 claims 1
- SYSRIKNTGFJCSF-UHFFFAOYSA-N n-methyl-n-(pyrrolidin-3-ylmethyl)-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCNC1 SYSRIKNTGFJCSF-UHFFFAOYSA-N 0.000 claims 1
- LHAGMOZZQUXOGT-UHFFFAOYSA-N n-methyl-n-[(3-methyl-1,2-oxazol-5-yl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC(C)=NO1 LHAGMOZZQUXOGT-UHFFFAOYSA-N 0.000 claims 1
- WUQJAIUIPSLVMN-UHFFFAOYSA-N n-methyl-n-[(3-oxocyclobutyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CC(=O)C1 WUQJAIUIPSLVMN-UHFFFAOYSA-N 0.000 claims 1
- IRCSTPRQTVOZNC-UHFFFAOYSA-N n-methyl-n-[(4-methylidenecyclohexyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1CCC(=C)CC1 IRCSTPRQTVOZNC-UHFFFAOYSA-N 0.000 claims 1
- FAFXZDGVCUCCMZ-UHFFFAOYSA-N n-methyl-n-[(4-methylsulfonylphenyl)methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC1=CC=C(S(C)(=O)=O)C=C1 FAFXZDGVCUCCMZ-UHFFFAOYSA-N 0.000 claims 1
- JCJXXXUMLHAIRS-CYBMUJFWSA-N n-methyl-n-[[(2r)-5-oxopyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCC(=O)N1 JCJXXXUMLHAIRS-CYBMUJFWSA-N 0.000 claims 1
- DIVAVHINIHYTBQ-CQSZACIVSA-N n-methyl-n-[[(2r)-pyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@H]1CCCN1 DIVAVHINIHYTBQ-CQSZACIVSA-N 0.000 claims 1
- DLQYDROUVYFJPX-HNNXBMFYSA-N n-methyl-n-[[(2s)-1-methylsulfonylpyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@@H]1CCCN1S(C)(=O)=O DLQYDROUVYFJPX-HNNXBMFYSA-N 0.000 claims 1
- JCJXXXUMLHAIRS-ZDUSSCGKSA-N n-methyl-n-[[(2s)-5-oxopyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@@H]1CCC(=O)N1 JCJXXXUMLHAIRS-ZDUSSCGKSA-N 0.000 claims 1
- DIVAVHINIHYTBQ-AWEZNQCLSA-N n-methyl-n-[[(2s)-pyrrolidin-2-yl]methyl]-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C[C@@H]1CCCN1 DIVAVHINIHYTBQ-AWEZNQCLSA-N 0.000 claims 1
- JDXKUXCSKKZLLG-UHFFFAOYSA-N n-methyl-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]cyclopentanecarboxamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C(=O)C1CCCC1 JDXKUXCSKKZLLG-UHFFFAOYSA-N 0.000 claims 1
- UQPSNJBBYOKOGM-UHFFFAOYSA-N n-methyl-n-phenacyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)CC(=O)C1=CC=CC=C1 UQPSNJBBYOKOGM-UHFFFAOYSA-N 0.000 claims 1
- CIGKTCDFFAKRJN-UHFFFAOYSA-N n-methyl-n-phenyl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)C1=CC=CC=C1 CIGKTCDFFAKRJN-UHFFFAOYSA-N 0.000 claims 1
- RKBWDKYOMREEBB-UHFFFAOYSA-N n-methyl-n-phenylmethoxy-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)N(C)OCC1=CC=CC=C1 RKBWDKYOMREEBB-UHFFFAOYSA-N 0.000 claims 1
- RTAKUAFBDVROFX-UHFFFAOYSA-N n-methyl-n-propan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CC(C)N(C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 RTAKUAFBDVROFX-UHFFFAOYSA-N 0.000 claims 1
- XQOVWVQOSYRSQW-UHFFFAOYSA-N n-pentan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CCCC(C)NS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 XQOVWVQOSYRSQW-UHFFFAOYSA-N 0.000 claims 1
- JJUSREYAJYCMFX-UHFFFAOYSA-N n-phenylmethoxy-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CC2(CC2)N1S(=O)(=O)NOCC1=CC=CC=C1 JJUSREYAJYCMFX-UHFFFAOYSA-N 0.000 claims 1
- OTCDORFSTSKFAZ-UHFFFAOYSA-N n-propan-2-yl-7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound CC(C)NS(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 OTCDORFSTSKFAZ-UHFFFAOYSA-N 0.000 claims 1
- NYIHEUQYLJRFCF-UHFFFAOYSA-N tert-butyl 4-[4-[2-phenylethyl(3-phenylpropyl)sulfamoyl]-4,7-diazaspiro[2.5]octan-7-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate Chemical compound N1=CN=C2N(C(=O)OC(C)(C)C)C=CC2=C1N(C1)CCN(S(=O)(=O)N(CCCC=2C=CC=CC=2)CCC=2C=CC=CC=2)C21CC2 NYIHEUQYLJRFCF-UHFFFAOYSA-N 0.000 claims 1
- LFWGRZMIQLTLEY-UHFFFAOYSA-N tert-butyl n-(3-methylsulfonylpropyl)-n-[[7-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octan-4-yl]sulfonyl]carbamate Chemical compound CS(=O)(=O)CCCN(C(=O)OC(C)(C)C)S(=O)(=O)N1CCN(C=2C=3C=CNC=3N=CN=2)CC11CC1 LFWGRZMIQLTLEY-UHFFFAOYSA-N 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 abstract description 3
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 642
- 238000005160 1H NMR spectroscopy Methods 0.000 description 210
- 239000000543 intermediate Substances 0.000 description 160
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 158
- 239000011541 reaction mixture Substances 0.000 description 72
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 238000000746 purification Methods 0.000 description 28
- 238000002953 preparative HPLC Methods 0.000 description 24
- 238000009472 formulation Methods 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000003480 eluent Substances 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 7
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010024121 Janus Kinases Proteins 0.000 description 6
- 102000015617 Janus Kinases Human genes 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000008986 Janus Human genes 0.000 description 4
- 108050000950 Janus Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- QWOKKHXWFDAJCZ-UHFFFAOYSA-N octane-1-sulfonamide Chemical compound CCCCCCCCS(N)(=O)=O QWOKKHXWFDAJCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 3
- XVUYNNMVJLUTMJ-UHFFFAOYSA-N 2-(2-phenylethylamino)acetonitrile Chemical compound N#CCNCCC1=CC=CC=C1 XVUYNNMVJLUTMJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000013264 Interleukin-23 Human genes 0.000 description 3
- 108010065637 Interleukin-23 Proteins 0.000 description 3
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 3
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MAJZIADXPBFMQN-UHFFFAOYSA-N 1,1-dioxo-3-[(sulfamoylamino)methyl]thiolane Chemical compound NS(=O)(=O)NCC1CCS(=O)(=O)C1 MAJZIADXPBFMQN-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- PMTLRCDQMKXMRZ-UHFFFAOYSA-N 1h-imidazole-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CN1 PMTLRCDQMKXMRZ-UHFFFAOYSA-N 0.000 description 2
- WPOHVHKEDGUEPZ-UHFFFAOYSA-N 2-(2-phenylethylamino)ethanol Chemical compound OCCNCCC1=CC=CC=C1 WPOHVHKEDGUEPZ-UHFFFAOYSA-N 0.000 description 2
- VVFCJVLORNFVHI-UHFFFAOYSA-N 2-(methylamino)-1-phenylethanone Chemical compound CNCC(=O)C1=CC=CC=C1 VVFCJVLORNFVHI-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- MYJFFRMEBNWEQO-UHFFFAOYSA-N 2-methyl-n-(2-phenylethyl)propan-1-amine Chemical compound CC(C)CNCCC1=CC=CC=C1 MYJFFRMEBNWEQO-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- OKWAOQJCZKZJOA-UHFFFAOYSA-N 4,7-diazaspiro[2.5]octane-4-sulfonamide Chemical compound C1CC12CNCCN2S(=O)(=O)N OKWAOQJCZKZJOA-UHFFFAOYSA-N 0.000 description 2
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 2
- 230000035986 JAK-STAT signaling Effects 0.000 description 2
- 108010019421 Janus Kinase 3 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- HJZVHUQSQGITAM-UHFFFAOYSA-N butanamide Chemical compound CC[CH]C(N)=O HJZVHUQSQGITAM-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 2
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 2
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 2
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- QSOCODZVGPDGDA-UHFFFAOYSA-N n,3-dimethylbutan-1-amine Chemical compound CNCCC(C)C QSOCODZVGPDGDA-UHFFFAOYSA-N 0.000 description 2
- MNWXPJSEFTZSDU-UHFFFAOYSA-N n-(2-methoxyethyl)-2-phenylethanamine Chemical compound COCCNCCC1=CC=CC=C1 MNWXPJSEFTZSDU-UHFFFAOYSA-N 0.000 description 2
- IIIRPZWDICEMGU-UHFFFAOYSA-N n-(2-phenylethyl)propan-1-amine Chemical compound CCCNCCC1=CC=CC=C1 IIIRPZWDICEMGU-UHFFFAOYSA-N 0.000 description 2
- VROYJSDEJAZEAO-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-phenylethanamine Chemical compound C1CCCCC1CNCCC1=CC=CC=C1 VROYJSDEJAZEAO-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KDVKENMVPSUFTF-UHFFFAOYSA-N n-cyclobutylsulfamoyl chloride Chemical compound ClS(=O)(=O)NC1CCC1 KDVKENMVPSUFTF-UHFFFAOYSA-N 0.000 description 2
- OOTKJPZEEVPWCR-UHFFFAOYSA-N n-methyl-1-pyridin-2-ylmethanamine Chemical compound CNCC1=CC=CC=N1 OOTKJPZEEVPWCR-UHFFFAOYSA-N 0.000 description 2
- UGOZVQRJDQYTKT-UHFFFAOYSA-N n-methyl-2-pyrrol-1-ylethanamine Chemical compound CNCCN1C=CC=C1 UGOZVQRJDQYTKT-UHFFFAOYSA-N 0.000 description 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
- UJJUEJRWNWVHCM-UHFFFAOYSA-N n-methylsulfamoyl chloride Chemical compound CNS(Cl)(=O)=O UJJUEJRWNWVHCM-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 2
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 2
- JWEQRJSCTFBRSI-PCLIKHOPSA-N rboxylate Chemical compound COC(=O)C1C(N2C3=O)C4=CC=CC=C4OC1(C)N=C2S\C3=C\C(C=1)=CC=C(OC)C=1COC1=CC=CC=C1C JWEQRJSCTFBRSI-PCLIKHOPSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- KAJZZLBZXOBEMD-UHFFFAOYSA-N tert-butyl n-chlorosulfonylcarbamate Chemical compound CC(C)(C)OC(=O)NS(Cl)(=O)=O KAJZZLBZXOBEMD-UHFFFAOYSA-N 0.000 description 2
- NFZLPULKDNRALQ-UHFFFAOYSA-N thiane-4-carboxamide Chemical compound NC(=O)C1CCSCC1 NFZLPULKDNRALQ-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- YUXHURBBBVGCBC-UHFFFAOYSA-N thiolane-3-carboxamide Chemical compound NC(=O)C1CCSC1 YUXHURBBBVGCBC-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YCTRDJGHVGMYAO-UHFFFAOYSA-N (1,1-dioxothiolan-3-yl)methanamine Chemical compound NCC1CCS(=O)(=O)C1 YCTRDJGHVGMYAO-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- FXGMEXPHHNLIII-UHFFFAOYSA-N 1,1-dioxothiolane-3-carbonyl chloride Chemical compound ClC(=O)C1CCS(=O)(=O)C1 FXGMEXPHHNLIII-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- IMHPOXSWOGMMNZ-UHFFFAOYSA-N 1,2-diazaspiro[2.5]octane-4-sulfonamide Chemical compound N1NC12CCCCC2S(=O)(=O)N IMHPOXSWOGMMNZ-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- XMPVAJVCLFYBKZ-UHFFFAOYSA-N 1-cyano-2-(sulfamoylamino)ethane Chemical compound NS(=O)(=O)NCCC#N XMPVAJVCLFYBKZ-UHFFFAOYSA-N 0.000 description 1
- IWHLPMBLJZJCJK-UHFFFAOYSA-N 1-cyclohexyl-n-methylmethanamine Chemical compound CNCC1CCCCC1 IWHLPMBLJZJCJK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JRHPOFJADXHYBR-UHFFFAOYSA-N 1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC JRHPOFJADXHYBR-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HNJWKRMESUMDQE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 description 1
- RDKFMYLRDJVSJU-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-methylethanamine Chemical compound CNCCC1=CC=CC(F)=C1 RDKFMYLRDJVSJU-UHFFFAOYSA-N 0.000 description 1
- NCBPDSPIVAMJIT-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(F)C=C1 NCBPDSPIVAMJIT-UHFFFAOYSA-N 0.000 description 1
- PJPREWNCIPMGIS-UHFFFAOYSA-N 2-(sulfamoylamino)ethylbenzene Chemical compound NS(=O)(=O)NCCC1=CC=CC=C1 PJPREWNCIPMGIS-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LGAJYTCRJPCZRJ-UHFFFAOYSA-N 2-bromopentane Chemical compound CCCC(C)Br LGAJYTCRJPCZRJ-UHFFFAOYSA-N 0.000 description 1
- KCYFTGSOYOWCJF-UHFFFAOYSA-N 2-cyclohexyl-n-methylethanamine Chemical compound CNCCC1CCCCC1 KCYFTGSOYOWCJF-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- OZHWHTICSNFGBZ-UHFFFAOYSA-N 3-(cyclopropylamino)propanenitrile Chemical compound N#CCCNC1CC1 OZHWHTICSNFGBZ-UHFFFAOYSA-N 0.000 description 1
- NKRJCZDAKAUEQI-UHFFFAOYSA-N 3-(sulfamoylamino)oxetane Chemical compound NS(=O)(=O)NC1COC1 NKRJCZDAKAUEQI-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- XPXXXQZNUQAFQY-UHFFFAOYSA-N 3-methylsulfonylpropan-1-ol Chemical compound CS(=O)(=O)CCCO XPXXXQZNUQAFQY-UHFFFAOYSA-N 0.000 description 1
- VVBAHFKQTKRMAS-UHFFFAOYSA-N 4-(bromomethyl)-1,1-difluorocyclohexane Chemical compound FC1(F)CCC(CBr)CC1 VVBAHFKQTKRMAS-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- 229910014455 Ca-Cb Inorganic materials 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- MKHGIGKNUOWWML-UHFFFAOYSA-N N-(2-cyanoethyl)-N-cyclopropylimidazole-1-sulfonamide Chemical compound C1=CN=CN1S(=O)(=O)N(CCC#N)C1CC1 MKHGIGKNUOWWML-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- SGZAHUMPHRLPIN-UHFFFAOYSA-N N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylimidazole-1-sulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)S(=O)(=O)N1C=NC=C1 SGZAHUMPHRLPIN-UHFFFAOYSA-N 0.000 description 1
- LDDSBCRSGPZIQK-UHFFFAOYSA-N N-benzyl-N-(2-cyanoethyl)imidazole-1-sulfonamide Chemical compound C1=CN=CN1S(=O)(=O)N(CCC#N)CC1=CC=CC=C1 LDDSBCRSGPZIQK-UHFFFAOYSA-N 0.000 description 1
- GNHHBKHNKAMKSM-UHFFFAOYSA-N N-methyl-N-(2-phenylethyl)imidazole-1-sulfonamide Chemical compound C1=CN=CN1S(=O)(=O)N(C)CCC1=CC=CC=C1 GNHHBKHNKAMKSM-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100029000 Prolactin receptor Human genes 0.000 description 1
- 101710117018 Prolactin receptor Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108700036252 Tyrosine Kinase 2 Deficiency Proteins 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ZAIQBJPTOXDDKA-LBPRGKRZSA-N [(2s)-1-benzylpyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1CC1=CC=CC=C1 ZAIQBJPTOXDDKA-LBPRGKRZSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000006294 amino alkylene group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- SCFYMUJVWKPQPO-UHFFFAOYSA-N cyano-(sulfamoylamino)methane Chemical compound NS(=O)(=O)NCC#N SCFYMUJVWKPQPO-UHFFFAOYSA-N 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- NFAZOGXQOWEWBM-UHFFFAOYSA-N cyclobutanamine;hydrochloride Chemical compound Cl.NC1CCC1 NFAZOGXQOWEWBM-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004050 homopiperazines Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000018615 immunodeficiency 35 Diseases 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- KPNIACYOHJGPJY-UHFFFAOYSA-N n-(cyanomethyl)-n-cyclopropylimidazole-1-sulfonamide Chemical compound C1=CN=CN1S(=O)(=O)N(CC#N)C1CC1 KPNIACYOHJGPJY-UHFFFAOYSA-N 0.000 description 1
- PJBAOQPVKJPENU-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-phenylethanamine Chemical compound C1CC1CNCCC1=CC=CC=C1 PJBAOQPVKJPENU-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- CELWCAITJAEQNL-UHFFFAOYSA-N oxan-2-ol Chemical compound OC1CCCCO1 CELWCAITJAEQNL-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ZGNXATVKGIJQGC-UHFFFAOYSA-N piperidine-3-carbonitrile Chemical compound N#CC1CCCNC1 ZGNXATVKGIJQGC-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220092886 rs143733205 Human genes 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- UKHWJBVVWVYFEY-UHFFFAOYSA-M silver;hydroxide Chemical compound [OH-].[Ag+] UKHWJBVVWVYFEY-UHFFFAOYSA-M 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical class NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- NQNGQGISAMHLST-UHFFFAOYSA-N tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CBr)C1 NQNGQGISAMHLST-UHFFFAOYSA-N 0.000 description 1
- XNLYPHAMXHERHS-UHFFFAOYSA-N tert-butyl 4,7-diazaspiro[2.5]octane-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC11CC1 XNLYPHAMXHERHS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430670P | 2011-01-07 | 2011-01-07 | |
| US61/430,670 | 2011-01-07 | ||
| PCT/EP2012/050187 WO2012093169A1 (en) | 2011-01-07 | 2012-01-06 | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2823935A1 true CA2823935A1 (en) | 2012-07-12 |
Family
ID=45478318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2823935A Abandoned CA2823935A1 (en) | 2011-01-07 | 2012-01-06 | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9233964B2 (enExample) |
| EP (1) | EP2661436B1 (enExample) |
| JP (1) | JP2014501772A (enExample) |
| KR (1) | KR20140058402A (enExample) |
| CN (1) | CN103298817A (enExample) |
| AU (1) | AU2012204843A1 (enExample) |
| BR (1) | BR112013017184A2 (enExample) |
| CA (1) | CA2823935A1 (enExample) |
| MX (1) | MX2013007792A (enExample) |
| RU (1) | RU2013136906A (enExample) |
| TW (1) | TW201309703A (enExample) |
| WO (1) | WO2012093169A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015178955A1 (en) * | 2014-05-19 | 2015-11-26 | Eternity Bioscience Inc. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| RU2658008C2 (ru) | 2014-06-24 | 2018-06-19 | Тайхо Фармасьютикал Ко., Лтд. | Новое пирролопиримидиновое соединение или его соль, фармацевтическая композиция, содержащая ее, в частности, агент для предотвращения и/или лечения опухолей, и тому подобное, на основе ингибиторного воздействия на nae |
| CN110291090A (zh) * | 2017-01-20 | 2019-09-27 | 利奥制药有限公司 | 作为新型jak激酶抑制剂的双环胺 |
| JP7101176B2 (ja) * | 2017-02-03 | 2022-07-14 | レオ ファーマ アクティーゼルスカブ | 新規ＪＡＫキナーゼ阻害剤としての５－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－５－アザスピロ［２．５］オクタン－８－カルボン酸誘導体 |
| CN108822048A (zh) * | 2018-07-23 | 2018-11-16 | 上海昌肽生物科技有限公司 | 4-(4-乙基-4,7二氮杂螺环[3,3]辛基)-2-硝基苯胺的合成工艺 |
| CN116730927A (zh) * | 2023-03-21 | 2023-09-12 | 广州佳途科技股份有限公司 | 一种新型高效合成4,7-二氮杂螺[2.5]辛烷盐酸盐的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| PL198640B1 (pl) | 1998-06-19 | 2008-07-31 | Pfizer Prod Inc | Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków |
| EA006227B1 (ru) * | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| CA2502356A1 (en) * | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US20050130954A1 (en) | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
| CA2545192A1 (en) | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| CA2549485A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| US7745436B2 (en) * | 2004-04-13 | 2010-06-29 | Synta Pharmaceuticals Corporation | Disalt inhibitors of IL-12 production |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1844050B1 (en) | 2005-02-03 | 2009-01-14 | Vertex Pharmaceuticals, Inc. | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| KR20080016659A (ko) | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| SG169369A1 (en) | 2006-02-02 | 2011-03-30 | Millennium Pharm Inc | Inhibitors of e1 activating enzymes |
| JP2009533323A (ja) | 2006-03-11 | 2009-09-17 | ヴァーナリス アールアンドディー リミテッド | Ｈｓｐ９０阻害剤として用いられるピロロピリミジン誘導体 |
| GB0604944D0 (en) * | 2006-03-11 | 2006-04-19 | Vernalis R&D Ltd | Pyrrolopyrimidine compounds |
| CA2648250A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| CA2682733A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
| PT2188289E (pt) | 2007-08-08 | 2015-12-21 | Lexicon Pharmaceuticals Inc | (7h-pirrolo[2,3-d]pirimidin-4-il)piperazinas como inibidores de quinases para o tratamento de cancro e de inflamação |
| BR112012000422A2 (pt) * | 2009-07-08 | 2017-05-09 | Leo Pharma As | composto, composição farmacêutica, uso de um composto, e, método para a prevenir tratar ou melhorar doenças do sistema imune |
-
2012
- 2012-01-06 KR KR1020137020834A patent/KR20140058402A/ko not_active Withdrawn
- 2012-01-06 BR BR112013017184A patent/BR112013017184A2/pt not_active IP Right Cessation
- 2012-01-06 WO PCT/EP2012/050187 patent/WO2012093169A1/en not_active Ceased
- 2012-01-06 CN CN2012800048283A patent/CN103298817A/zh active Pending
- 2012-01-06 US US13/977,408 patent/US9233964B2/en not_active Expired - Fee Related
- 2012-01-06 JP JP2013547865A patent/JP2014501772A/ja active Pending
- 2012-01-06 MX MX2013007792A patent/MX2013007792A/es not_active Application Discontinuation
- 2012-01-06 RU RU2013136906/04A patent/RU2013136906A/ru not_active Application Discontinuation
- 2012-01-06 EP EP12700266.5A patent/EP2661436B1/en not_active Not-in-force
- 2012-01-06 CA CA2823935A patent/CA2823935A1/en not_active Abandoned
- 2012-01-06 AU AU2012204843A patent/AU2012204843A1/en not_active Abandoned
- 2012-01-09 TW TW101100842A patent/TW201309703A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013007792A (es) | 2013-07-30 |
| WO2012093169A1 (en) | 2012-07-12 |
| KR20140058402A (ko) | 2014-05-14 |
| EP2661436B1 (en) | 2016-04-13 |
| US20130345194A1 (en) | 2013-12-26 |
| EP2661436A1 (en) | 2013-11-13 |
| JP2014501772A (ja) | 2014-01-23 |
| TW201309703A (zh) | 2013-03-01 |
| US9233964B2 (en) | 2016-01-12 |
| BR112013017184A2 (pt) | 2016-09-20 |
| RU2013136906A (ru) | 2015-02-20 |
| CN103298817A (zh) | 2013-09-11 |
| AU2012204843A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019317625B2 (en) | Pyrrolopyrimidine ITK inhibitors | |
| JP7248256B2 (ja) | Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用 | |
| EP3463343B1 (en) | Heterocyclic inhibitors of ptpn11 | |
| JP6881879B2 (ja) | Ｊａｋキナーゼ阻害剤としてのピリミジン化合物 | |
| EP2590981B1 (en) | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| RS59911B1 (sr) | Selektivno supstituisana jedinjenja hinolina | |
| CA2767079A1 (en) | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors | |
| RU2764980C2 (ru) | Бициклические амины в качестве новых ингибиторов jak-киназы | |
| CN105164114A (zh) | C-连接的杂环烷基取代的嘧啶类和它们的用途 | |
| TW202106681A (zh) | 用於治療皮膚疾病之嘧啶jak抑制劑 | |
| WO2015178955A1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| EP2661436B1 (en) | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| EP3576743B1 (en) | 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors | |
| HK30089209A2 (en) | Hpk1 kinase inhibitor compound | |
| HK1188449A (en) | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160106 |